VIR vs. FDMT, TARS, NMRA, CGEM, SRRK, BCRX, AUTL, IMTX, INBX, and PROK
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include 4D Molecular Therapeutics (FDMT), Tarsus Pharmaceuticals (TARS), Neumora Therapeutics (NMRA), Cullinan Oncology (CGEM), Scholar Rock (SRRK), BioCryst Pharmaceuticals (BCRX), Autolus Therapeutics (AUTL), Immatics (IMTX), Inhibrx (INBX), and ProKidney (PROK). These companies are all part of the "biological products, except diagnostic" industry.
Vir Biotechnology (NASDAQ:VIR) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends.
65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 15.6% of Vir Biotechnology shares are owned by company insiders. Comparatively, 7.3% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Vir Biotechnology has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.94, suggesting that its stock price is 194% more volatile than the S&P 500.
In the previous week, 4D Molecular Therapeutics had 13 more articles in the media than Vir Biotechnology. MarketBeat recorded 14 mentions for 4D Molecular Therapeutics and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.89 beat 4D Molecular Therapeutics' score of 0.53 indicating that Vir Biotechnology is being referred to more favorably in the media.
Vir Biotechnology currently has a consensus target price of $33.57, indicating a potential upside of 245.03%. 4D Molecular Therapeutics has a consensus target price of $44.22, indicating a potential upside of 74.52%. Given Vir Biotechnology's higher possible upside, equities research analysts clearly believe Vir Biotechnology is more favorable than 4D Molecular Therapeutics.
4D Molecular Therapeutics has lower revenue, but higher earnings than Vir Biotechnology. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
4D Molecular Therapeutics has a net margin of -436.30% compared to Vir Biotechnology's net margin of -677.69%. 4D Molecular Therapeutics' return on equity of -26.75% beat Vir Biotechnology's return on equity.
Vir Biotechnology received 5 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. However, 65.38% of users gave 4D Molecular Therapeutics an outperform vote while only 48.15% of users gave Vir Biotechnology an outperform vote.
Summary
4D Molecular Therapeutics beats Vir Biotechnology on 12 of the 18 factors compared between the two stocks.
Get Vir Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
Related Companies and Tools
